GLP-1 Weight Loss Drugs
4 articles on GLP-1 Weight Loss Drugs, written by Shotlee and medically reviewed for clinical accuracy.
Lindt: GLP-1 Users Eating More Chocolate, Not Less
Contrary to predictions, chocolate sales are surging among GLP-1 weight-loss drug users in the U.S., according to Swiss chocolatier Lindt & Spruengli. An internal analysis reveals these households account for 17.5% of chocolate purchases, with premium varieties rising nearly 17%. This challenges assumptions about appetite suppression from drugs like Ozempic and Mounjaro.
5 min read
Study Finds Some Patients Keep Weight Off with Fewer GLP-1 Injections
A new study shows that some patients on GLP-1 drugs like Wegovy can space out injections every other week or longer and still keep weight off. Led by Dr. Mitch Biermann at Scripps Clinic, the research followed 34 patients who maintained health gains after reducing frequency. Experts say this reframes long-term obesity treatment discussions.
5 min read
Weight-Loss Drugs Compete in Super Bowl Ads: Wegovy Leads
Weight-loss drugs like Wegovy's new pill are making a splash with multimillion-dollar Super Bowl ads featuring Kenan Thompson, DJ Khaled, and Serena Williams. As Novo Nordisk and Eli Lilly battle for market share, affordable oral GLP-1 options starting at $49 signal a new era in obesity care. See how these celebrity spots aim to reach 130 million viewers.
5 min read
Super Bowl LX Ads Feature AI, GLP-1 Drugs & Celebs from Clooney to Jenner
Super Bowl LX is set to showcase a surge in GLP-1 weight-loss drug ads from telehealth giants like Ro featuring Serena Williams and Novo Nordisk's Ozempic and Wegovy. With record $8-10M ad slots, health trends dominate alongside AI and celebrity-packed spots with George Clooney and Kendall Jenner. This 'GLP-1 Super Bowl' highlights booming demand for metabolic health solutions.
6 min read